Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

From San Diego, A Great Debate on Biosimilars

Published: Tue, 21 Nov 2017 19:10:09 EST
Dr Jonathan Kay provides an overview of news and views on biosimilars to be presented at ACR 2017.
Medscape Rheumatology

FOURIER: Aim PCSK9 Inhibitors at Highest of High-Risk Patients?

Published: Tue, 21 Nov 2017 17:04:55 EST
"Not all of our patients with CV disease can have these expensive medications," says an observer. Subanalyses of FOURIER provide possible guides to their selective use in secondary prevention.
Medscape Medical News

Are You Considering Private Practice?

Published: Tue, 21 Nov 2017 16:39:18 EST
While private practice may never again dominate the healthcare landscape, it's likely to remain a small but permanent fixture.
Medscape Reader Polls

EHR Vendor Sued for $1 Billion Over Record Accuracy

Published: Tue, 21 Nov 2017 15:53:03 EST
The lawsuit against eClinicalWorks seeks class-action status for all patients whose physicians use its software, accused of messing up patient data.
Medscape Medical News
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Toxicity knocks Ardelyx's hyperkalemia hopes back to preclinic

Published: Tue, 21 Nov 2017 13:48:17 +0000
Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

Cytokinetics cans lead drug after phase 3 ALS wipeout

Published: Tue, 21 Nov 2017 13:37:33 +0000
Cytokinetics has stopped development of its lead drug. The San Francisco-based biotech made the decision after tirasemtiv failed to beat placebo against the primary endpoint or any of the secondary goals in a study of more than 700 patients with amyotrophic lateral sclerosis (ALS).

Step Pharma bags cash for CTPS1 autoimmune R&D drive

Published: Tue, 21 Nov 2017 07:45:23 +0000
Step Pharma has closed a €14.5 million ($17.0 million) series A round. The financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

DBV climbs as peanut allergy safety data come in clean

Published: Mon, 20 Nov 2017 14:15:16 +0000
DBV Technologies has posted phase 3 data suggesting safety and compliance are unlikely to scuttle its hopes of winning approval of peanut allergy treatment Viaskin Peanut. Shares in DBV rose on the back of the data, going a little way toward erasing the big drop it suffered after missing its primary efficacy endpoint.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy